Previsioni

Non sono disponibili dati degli analisti per questa azienda.

Notizie Vai al feed delle notizie

Santhera: phase‑1 topline for AGAMREE® shows glucocorticoid activity without meaningful immunosuppression

Santhera reports topline results from a Phase‑1 study of AGAMREE® conducted by Catalyst, which show glucocorticoid and anti‑inflammatory effects at clinical doses but only minor immunosuppressive biomarker effects. Relevant immunosuppressive effects were observed only at doses above the currently approved AGAMREE dosage. Catalyst holds North American rights for DMD and potential follow‑on indications; Santhera retains pre‑negotiation rights outside North America and is entitled to sales‑based milestones and royalties. » Altro su finanzen.net
Santhera reports 98% revenue growth in 2025 driven by AGAMREE

Santhera recorded a 98% increase in total revenue in 2025 to CHF 77.4 million, driven by strong uptake of AGAMREE in Europe and the US as well as license and milestone receipts. Product sales rose to CHF 25.8 million and license and milestone payments to CHF 23.1 million; Catalyst paid a milestone of USD 12.5 million after US sales exceeded USD 100 million. After year-end, Santhera signed an exclusive license agreement with Nxera worth up to USD 205 million, which included an upfront payment of USD 40 million. Cash and cash equivalents amounted to CHF 22.4 million as of 31.12.2025 (excluding the Nxera upfront), and the company expects cash-flow break-even in Q3 2026 without additional financing. » Altro su finanzen.net
Santhera appoints Marc Clausse as chief commercial officer

Santhera Pharmaceuticals has appointed Marc Clausse as chief commercial officer (CCO). Clausse will assume responsibility for leading the company’s commercial activities. » Altro su finanzen.net

Dati finanziari dell'azienda

Nell'ultimo trimestre, Santhera Pharma Aktie ha registrato ricavi pari a 57,11 Mln € e un utile netto di -11,17 Mln €

(EUR)	dic 2025	YoY
Ricavi	57,11 Mln	-
Utile lordo	24,62 Mln	-
Utile netto	-11,17 Mln	-
EBITDA	515,54K	-

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	213,97 Mln €
Numero di azioni	13,01 Mln
Massimo/minimo a 52 settimane	16,63 € - 6,55 €
Dividendi	No
Beta	-0,28
Rapporto P/E	-4,04
Rapporto PEG	0,13
Rapporto P/B	-17,48
Rapporto P/S	2,96

Profilo aziendale

Santhera Pharmaceuticals Holding AG, ein Spezialitätenpharmaunternehmen, entwickelt und vermarktet zusammen mit ihren Tochtergesellschaften Medikamente für seltene neuromuskuläre und pulmonale Krankheiten mit hohem medizinischem Bedarf in der Europäischen Union und international. Der wichtigste Kandidat in der Pipeline des Unternehmens ist Vamorolon, das zur Behandlung der Duchenne-Muskeldystrophie (DMD) entwickelt wird. Seine Pipeline im klinischen Stadium umfasst auch Lonodelestat (POL6014) zur Behandlung von zystischer Fibrose und anderen neutrophilen Lungenerkrankungen sowie Omigapil zur Behandlung kongenitaler Muskeldystrophien. Das Unternehmen lizenziert ausserhalb Nordamerikas und Frankreichs auch die Rechte an seinem zugelassenen Produkt Raxone (Idebenone) zur Behandlung der hereditären Leberschen Optikusneuropathie aus. Die Santhera Pharmaceuticals Holding AG wurde 2004 gegründet und hat ihren Hauptsitz in Pratteln, Schweiz.

Nome	Santhera Pharma Aktie
CEO	Orlando Oliveira
Sede centrale	Pratteln, bl Svizzera
Sito web	santhera.com
Settore	Sanità
Industria	Prodotti farmaceutici
Quotazione in borsa	06/03/2014
Dipendenti	78